Answers are grounded in this paper and cite their sources.
MANY women choose not to take estrogen replacement therapy (ERT) even though medical indications are present. For the estimated 2.5 million survivors of breast cancer in the United States, concern about breast cancer risk strongly influences their decision-making process. Because of successful treatment of in situ or Stage I breast cancer, many of these women are at low risk for recurrence. Nonetheless, they are concerned about taking ERT until well controlled studies examine the risk of recurrent or contralateral breast cancer and establish safety. A recent consensus conference reviewed available data and concluded that no properly randomized, placebo-controlled trials have examined the safety of ERT in survivors of breast cancer (1, 2). Other women have an absolute contraindication to the use of estrogen or are fearful of various side effects and risks associated with ERT. These considerations emphasize the need to evaluate alternative options for treatment of estrogen deficiency in selected patients.
No takes yet. Share an insight, caveat, or question.
Pinkerton et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: